Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
37 hedge funds and large institutions have $116M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 6 reducing their positions, and 7 closing their positions.
183% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 6
27% more capital invested
Capital invested by funds: $91.3M → $116M (+$25.1M)
3.37% more ownership
Funds ownership: 16.22% → 19.59% (+3.4%)
8% less funds holding
Funds holding: 40 → 37 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$13.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.14M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$3.3M |
| 4 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$2.71M |
| 5 |
BlackRock
New York
|
+$664K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.86M |
| 2 |
Goldman Sachs
New York
|
-$515K |
| 3 |
Two Sigma Investments
New York
|
-$360K |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$282K |
| 5 |
Renaissance Technologies
New York
|
-$171K |
ELOX Hedge Fund Activity: Q3 2018 in Review
37 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q3 2018, worth a combined $116M — up 27% from $91.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ELOX and 4 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 17 added.
The largest buyer was Altshuler Shaham, opening a new position worth an estimated $13.5M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.86M sold.
- 37 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q3 2018, down from 40 in Q2 2018.
- Funds reported $116M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q3 2018, up 27% quarter-over-quarter.
- 4 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q3 2018 and 7 closed out, a net change of -3 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q3 2018 was Altshuler Shaham, an estimated $13.5M added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q3 2018 was Sphera Funds Management, an estimated $2.86M sold.
Based on aggregated 13F filings for Q3 2018.